Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.

Yoichi Mizutani

Journal: International journal of urology : official journal of the Japanese Urological Association 2009;16(5):444-8

PMID: 19298634

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Advanced renal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy. Immunotherapy is relatively effective against RCC. However, the response rate is approximately 15-20%. Therefore, new therapeutic approaches are necessary. Recently, molecular mechanisms responsible for the proliferation of RCC are identified, and molecular targeted therapy is developed. Bevacizumab, sorafenib, sunitinib, axitinib, temsirolimus, everolimus are promising molecular targeted therapeutic agents for metastatic RCC, and will be used widely in clinics in the near future. In addition, combination therapy with molecular targeted therapy and other therapies including immunotherapy may also be developed soon.

Address: Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan. [email protected]

DOI: 10.1111/j.1442-2042.2009.02277.x

Link outs

Free resources

Medical:

https://medlineplus.gov/kidneycancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Benzenesulfonates, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Niacinamide, Phenylurea Compounds, Pyridines, Pyrroles, Sirolimus, Sorafenib, Sunitinib